Publicacions en col·laboració amb investigadors/es de Eli Lilly and Company (19)

2014

  1. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: A randomized, double-blind, placebo-controlled trial

    International Journal of Geriatric Psychiatry, Vol. 29, Núm. 9, pp. 978-986

2011

  1. Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: Post hoc analysis of a cross-sectional study

    BMC Psychiatry, Vol. 11

  2. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder

    Journal of Sexual Medicine, Vol. 8, Núm. 3, pp. 773-782

  3. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: Effectiveness and functional outcomes over a 6-month observational period

    International Journal of Psychiatry in Clinical Practice, Vol. 15, Núm. 4, pp. 242-254

2010

  1. Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: Prevalence of painful somatic symptoms, functioning and health status

    Journal of Affective Disorders, Vol. 127, Núm. 1-3, pp. 160-168

  2. Presence and predictors of pain in depression: Results from the FINDER study

    Journal of Affective Disorders, Vol. 125, Núm. 1-3, pp. 53-60

2009

  1. "Caseness" for depression and anxiety in a depressed outpatient population: Symptomatic outcome as a function of baseline diagnostic categories

    Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 11, Núm. 6, pp. 307-315

  2. Quality of life outcomes among patients with depression after 6 months of starting treatment: Results from FINDER

    Journal of Affective Disorders, Vol. 113, Núm. 3, pp. 296-302

  3. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: Effects on painful physical symptoms of depression

    Journal of Psychiatric Research, Vol. 43, Núm. 5, pp. 512-518

2008

  1. Factors influencing depression endpoints research (FINDER): Study design and population characteristics

    European Psychiatry, Vol. 23, Núm. 1, pp. 57-65

  2. Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study

    European Psychiatry, Vol. 23, Núm. 1, pp. 66-73

2006

  1. Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study

    British Journal of Psychiatry, Vol. 188, Núm. APR., pp. 346-353

  2. Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 Year follow-up naturalistic study

    Actas Espanolas de Psiquiatria, Vol. 34, Núm. 1, pp. 7-15

2005

  1. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 972-982

2004

  1. Estudio observacional paneuropeo de la efectividad de la olanzapina frente a otros antipsicóticos (SOHO): Resultados basales de la muestra española

    Actas Espanolas de Psiquiatria, Vol. 32, Núm. 4, pp. 227-235

2001

  1. Fluoxetine in the prevention of depressive recurrences: A double-blind study

    Journal of Clinical Psychopharmacology, Vol. 21, Núm. 4, pp. 417-424

2000

  1. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study

    Clinical Therapeutics, Vol. 22, Núm. 5, pp. 583-599

1999

  1. SSRI antidepressant use patterns and their relation to clinical global impression scores: A naturalistic study

    Journal of Affective Disorders, Vol. 52, Núm. 1-3, pp. 111-119

1998

  1. Patrón de uso de los nuevos antidepresivos en la práctica clínica

    Actas Espanolas de Psiquiatria, Vol. 26, Núm. 2, pp. 75-82